107 related articles for article (PubMed ID: 1786895)
21. Proposals for standardized protocols for cytogenetic analyses of acute leukemias, chronic lymphocytic leukemia, chronic myeloid leukemia, chronic myeloproliferative disorders, and myelodysplastic syndromes.
Haferlach C; Rieder H; Lillington DM; Dastugue N; Hagemeijer A; Harbott J; Stilgenbauer S; Knuutila S; Johansson B; Fonatsch C
Genes Chromosomes Cancer; 2007 May; 46(5):494-9. PubMed ID: 17311250
[TBL] [Abstract][Full Text] [Related]
22. Blood bioamines, cortisol and aminoacid levels in leukemic patients.
Singh JN; Chansouria JP; Singh VP; Udupa KN
Indian J Cancer; 1989 Dec; 26(4):222-6. PubMed ID: 2636208
[TBL] [Abstract][Full Text] [Related]
23. [The functional activity of blood neutrophils in chronic myeloleukemia].
Asadov ChD; Numerova LS
Lab Delo; 1990; (10):59-61. PubMed ID: 1704464
[No Abstract] [Full Text] [Related]
24. Leukocyte function in chronic myeloproliferative disorders.
Wolach B; Gavrieli R; Manor Y; Lishner M
Blood Cells Mol Dis; 1998 Dec; 24(4):544-51. PubMed ID: 9887281
[TBL] [Abstract][Full Text] [Related]
25. Hyperfunction of neutrophils in a patient with BCR/ABL negative chronic myeloid leukemia: a case report with in vitro studies.
Watari K; Tojo A; Nagamura-Inoue T; Matsuoka M; Irie S; Tani K; Yamada Y; Asano S
Cancer; 2000 Aug; 89(3):551-60. PubMed ID: 10931454
[TBL] [Abstract][Full Text] [Related]
26. Recent advances in biological and therapeutic aspects of myeloproliferative disorders.
Mancini M; Diverio D; Alimena G; Mandelli F
Curr Opin Hematol; 1994 Jul; 1(4):261-7. PubMed ID: 9371292
[TBL] [Abstract][Full Text] [Related]
27. [Chronic myeloid leukemia/chronic myeloproliferative disorders].
Ohyashiki K
Nihon Rinsho; 2007 Jan; 65 Suppl 1():250-3. PubMed ID: 17474419
[No Abstract] [Full Text] [Related]
28. Purine nucleotide content of polymorphonuclear leukocytes from acute and chronic myeloid leukemia patients.
Pagani R; Tabucchi A; Consolmagno E; Carlucci F; Pizzichini M; Marinello E; Leoncini R
Biochem Soc Trans; 1994 May; 22(2):243S. PubMed ID: 7958303
[No Abstract] [Full Text] [Related]
29. [Thyroid function in severe non-thyroidal diseases].
Földes J; Váradi G; Lakatos P; Bános C; Tarján G
Orv Hetil; 1989 Nov; 130(45):2415-8. PubMed ID: 2694058
[TBL] [Abstract][Full Text] [Related]
30. Imatinib does not inhibit neutrophil oxidative burst function in patients with chronic myelogenous leukemia.
Bizargity P; Adigüzel C; Ozilhan G; Bayik M; Eksioglu-Demiralp E
Clin Lab Haematol; 2005 Feb; 27(1):79-80. PubMed ID: 15686514
[No Abstract] [Full Text] [Related]
31. Detection of bcr-abl gene expression at a low level in blood cells of some patients with essential thrombocythemia.
Hsu HC; Tan LY; Au LC; Lee YM; Lieu CH; Tsai WH; You JY; Liu MD; Ho CK
J Lab Clin Med; 2004 Feb; 143(2):125-9. PubMed ID: 14966468
[TBL] [Abstract][Full Text] [Related]
32. Bcr-abl mRNA expression in patients with chronic myeloproliferative disorders--absence of bcr-abl fused clone except chronic myelocytic leukemia.
Nakata Y
Hiroshima J Med Sci; 1993 Jun; 42(2):67-71. PubMed ID: 8253600
[TBL] [Abstract][Full Text] [Related]
33. Clinicopathological features of unbalanced translocation Der(1;7)(q10;p10) in myeloid neoplasms.
So CC; Ma ES; Wan TS; Yip SF; Chan LC
Leuk Res; 2008 Jun; 32(6):1000-1. PubMed ID: 17980911
[No Abstract] [Full Text] [Related]
34. [The thrombocytic beta-thromboglobulin level of patients with blastic leukemia and chronic myeloleukemia].
Genova V; Kurtev I
Vutr Boles; 1988; 27(4):54-7. PubMed ID: 2975086
[TBL] [Abstract][Full Text] [Related]
35. Superoxide production of polymorphonuclear leukocytes in patients with hematological disorders.
Kitamura T; Tomonaga M
Nihon Ketsueki Gakkai Zasshi; 1983 Dec; 46(7):1487-96. PubMed ID: 6326454
[No Abstract] [Full Text] [Related]
36. Incidence and clinical significance of peripheral and bone marrow basophilia.
Arnalich F; Lahoz C; Larrocha C; Zamorano AF; Jimenez C; Gasalla R; Garcia-Puig J; Vazquez JJ
J Med; 1987; 18(5-6):293-303. PubMed ID: 3505257
[TBL] [Abstract][Full Text] [Related]
37. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
Tefferi A
Semin Hematol; 1999 Jan; 36(1 Suppl 2):3-8. PubMed ID: 9930550
[TBL] [Abstract][Full Text] [Related]
38. C3b receptor-negative peripheral blood neutrophils. A study of normal and haematologically abnormal disorders.
Scott CS; Bynoe AG; Hough D; Roberts BE
Scand J Haematol; 1984 Feb; 32(2):183-9. PubMed ID: 6230710
[TBL] [Abstract][Full Text] [Related]
39. [Alteration of platelet function in myeloproliferative disorder and its clinical significance].
Ni HY; Deng CG; Ruan HF; Pam CF; Li HR; Gon DQ
Hua Xi Yi Ke Da Xue Xue Bao; 1988 Sep; 19(3):312-6. PubMed ID: 3253181
[No Abstract] [Full Text] [Related]
40. [Testing the hemalog D in a hematology department of a general hospital in Paris (author's transl)].
Lortholary P; Lejeune F; Ganon JP; Mathiot C; Turpin F
Nouv Rev Fr Hematol (1978); 1978 Jun; 20(2):223-48. PubMed ID: 279890
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
